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ADDITIONAL METHODS

Histopathology.
Immunohistochemistry was performed using the Ventana BenchMark Ultra automated platform. Tissue sections were first deparaffinized using Ventana's "ez-prep" solution. Antigen retrieval was performed by treatment at 95°C for 54 minutes using Ventana's CC1 (pH 7.3) solution, followed by treatment with 0.3% hydrogen peroxide to block endogenous peroxidase. Tissue sections were then incubated in protein-free block (Biocare's background sniper) for 15min to inhibit nonspecific binding. Primary antibody (anti-Aβ 6E10 at 1:400, Biocare Medical) was incubated for 32 min at room temperature. Detection was performed using Ventana's ultraview DAB kit, and counterstaining with Gill hematoxylin solution. A boardcertified neuropathologist, who was blinded to the treatment versus the control group, analyzed a sagittal section from each mouse and counted the total number of well-formed β-amyloid plaques.
Calculation of Ligand Efficiency. Ligand efficiency was calculated using the following equation 1 : LE= (1.37/HA) * pIC50. We substituted the more accurate Ki value (101nM) from Michaelis-Menton analysis (above) for pIC50 and used the heavy atom (HA) count of 29. The calculated LE = 0.33 is above the prevailing bias in the computational field that such values should be > 0.3. It should be noted that such calculations are not validated for CNS drugs due to bias in the databases used.
General.
All NMR spectra were recorded on Bruker Avance III 500 MHz system equipped with a DCH CryoProbe and Mercury 300MHz FT-NMR spectrometer. Data are reported in the following order: chemical shifts δ values in ppm downfield with the deuterated solvents as are reported in parts per million (ppm) using tetramethylsilane (TMS) as an internal standard (signal = 0 ppm) (s-siglet, d= doublet, t= triplet, br= broad, m= multiplate), integration, coupling constant (Hz). Accurate-mass/ High-resolution mass spectrometry (HRMS) analysis was performed using an Agilent 6210A LC-TOF mass spectrometer in positive ion mode (ambient temperature). Melting points (mp) were taken in open capillaries on a Büchi Melting Point B-540 (Flawil, Switzerland) and are uncorrected. Elemental analysis was performed on a Perkin-Elmer 2400 Elemental Analyzer, Intertek Pharmaceutical Services, Whitehouse, NJ. LC/MS data were determined with a Waters Alliance 2695 HPLC/MS (Waters Symmetry C18, 4.6 X 75 mm, 3.5 lm) with a 2996 diode array detector from 210-400 nm; the solvent system is 5-95% ACN in water (0.1% TFA) over nine min using a linear gradient and retention times are in minutes. Mass spectrometry was performed on a Waters ZQ using electrospray in positive mode. Preparative reversed phase chromatography (RPHPLC), was performed on a Waters Sunfire column (19 X 50 mm, C18, 5 micron) with a mobile phase of 10% acetonitrile/water to 90% acetonitrile/water with 0.1% TFA as buffer using 214 nm and 254 nm as detection wavelengths. Injection and fraction collection were performed with a Gilson 215 liquid handling apparatus using Trilution LC software. Purity of al final compounds determined by HPLC (Dionex System, Sunnyvale, CA), with UVD170U ultraviolet detector and P680 pump. The column was a Phenomenex (Torrance, CA) Luna C18, 5 μm particle size (250mm x 2.0 mm), supported by Phenomenex Security Guard cartridge kit C18 (4.0mm x 2.0 mm) at a flow rate of 0.2 mL/min and using a mobile phase composed of 0.1% (v/v) formic acid (Fluka) in water as solvent A and 80% acetonitrile, 0.08% formic acid/water as solvent B. (gradient -0% to 100% B, 15 min; isocratic 22 min), compounds were analyzed at ~0.50 μg level and peak quantification was performed based upon Relative area % absorption at 260 nm. Unless otherwise noted, all synthesis was carried out in reagent grade solvents and was used as purchased without further purification unless otherwise stated. compound 10, 11, 12, 13 and 14 was made following the same Scheme 1 described in main text. N-dimethyl-6-(naphthalen-2-yl)-5-(pyridin-4-yl)pyridazin-3-amine (10 = MW108) . A solution of 3-bromo-6-(naphthalen-2-yl)-5-(pyridin-4-yl)pyridazine (7) (800 mg, 2.2 mmol) in 2 ethanol (20 ml) was treated with a solution of dimethylamine in ethanol (33%, 2mL).The mixture was sealed and heated to 90 °C for 18h. The reaction mixture was cooled to ambient temperature, diluted with ethyl acetate (25 ml), washed with saturated sodium bicarbonate (25 ml), water (25 ml) and brine (100 ml), washed with 1M sodium carbonate solution and brine. The organic phase was dried (Na 2 SO 4 ) and evaporated to a tan foamy solid that crystalized on standing (0.690g, 95%). 1 
Synthesis of
N,
6-(Azetidin-1-yl)-3-(naphthalen-2-yl)-4-(pyridin-4-yl)pyridazine (11= MW146).
A solution of compound 7 (35 mg, 0.097 mmol) in 200 proof ethanol (1 ml) was treated with azetidine (17 mg, 0.29 mmol, 20 μl). The mixture was sealed and heated to 85 °C for 15 hours then cooled to room temperature. The mixture was diluted with ethyl acetate (25 ml), washed with saturated sodium bicarbonate (25 ml), water (25 ml) and brine (25 ml), dried (MgSO 4 ) and evaporated. The product was triturated with hexane to leave a beige crystalline solid (32 mg, 98%). 1 
3-(Naphthalen-2-yl)-4-(pyridin-4-yl)-6-(pyrrolidin-1-yl)pyridazine (12= MW148).
A solution of compound 7 (50 mg, 0.14 mmol) and pyrrolidine (40 mg, 0.56 mmol, 46 μ) in 200 proof ethanol (2 ml) was sealed and heated to 85 °C for 15h. The mixture was diluted with ethyl acetate (25 ml), washed with saturated sodium bicarbonate (25 ml), water (25 ml) and brine (25 ml), dried (MgSO 4 ) and evaporated. The residue was purified by chromatography on silica gel eluted with a gradient of 75% ethyl acetate in hexane to 100% ethyl acetate. The product fractions were evaporated to leave a beige crystalline solid (41 mg, 83%). 1 -2-yl)-6-(piperidin-1-yl)-4-(pyridin-4-yl)pyridazine (13= MW086) . A solution of compound 7 (25 mg, 69 mmol) and piperidine (29 mg, 0.35 mmol, 34 ml) in ethanol (95%, 1 ml) was heated to reflux for 18 h. The mixture was purified by purified by preparative RPHPLC. The product fractions were combined and neutralized with saturated aqueous sodium bicarbonate solution (25 ml) and the product was extracted with ethyl acetate (2 X 25 ml). The extracts were washed with brine, dried (MgSO 4 ) and evaporated to leave 24 mg solid (95%). 1 -2-yl)-6-(piperazin-1-yl)-4-(pyridin-4-yl)pyridazine (14 = MW154) . A solution of compound 7 (50 mg, 0.14 mmol) and piperazine (59 mg, 0.69 mmol) in 95% ethanol (1 ml) was refluxed for 18 h. The reaction mixture was diluted with ethyl acetate (25 ml) and washed with saturated sodium bicarbonate solution (25 ml), water (2 X 25 ml), brine (25 ml), dried (Na 2 SO 4 ) and evaporated to a beige solid (50 mg, 97%). 1 Synthesis of compound compounds 15, 16, 17 and 18 was made following the discovery scheme S1 described below. Compound 8 was also synthesized following scheme S1. Scheme S1 3, 6-Dichloro-4-pyridine-4-yl)pyridazine (1). Prepared as previously described. 2 
3-(Naphthalen
3-Chloro-6-(4-methylpiperazin-1-yl)-4-(pyridin-4-yl)pyridazine (2)
. Following the published protocol 3 , a solution of compound 1 (0.750g, 3.3 mmol, 1eq) and 1-methylpiperazine (1.4g, 13.2 mmol) in 25ml ethanol were placed in a heavy wall pressure vessel (Chemglass, Vineland, NJ) and refluxed for 17h. The product was purified by column chromatography on silica gel (200-400 mesh) and eluted with 2% methanol and ethyl acetate providing product 2 (620 mg, 78%) as a beige powder. 1 
6-(4-Methylpiperazine-1-yl)-3-(naphthalen-2-yl)-4-(pyridin-4-yl)pyridazine (8= MW150).
A mixture of compound 2 (0.187g, 0.6mmol, 1eq) and 2-Napthylboronic acid (0.156g, 0.9mmol, 1.3eq) was suspended in dimethoxyethane (DME) and water (10:1 v/v) in a heavy wall pressure vessel and purged with argon for 5 min. Subsequently Tetrakis(triphenylphosphine) palladium (67mg, 9 mol %) , Na 2 CO 3 (0.212g, 2.0mmol) were added under argon , and followed the same protocol mentioned above. The crude product was purified by column chromatography on silica gel (200-400 mesh) using dichloromethane and 5% methanol followed by crystallization with ethyl acetate. The product 8 obtained (purity >97%) as beige color crystals in 68% (gravimetric) yield, mp 187.5-188 °C (uncorrected). 1 
3-(7-Fluoronaphthalen-2-yl)-6-(4-methylpiperazin-1-yl)-4-(pyridin-4-yl)pyridazine (16 = MW017).
A mixture compound 2 (46 mg, 0.16 mmol), (7-fluoronaphthalen-2-yl)boronic acid 5 (25 mg, 0.13 mmol), tetrakis(triphenylphosphine) palladium (15 mg, 13 mmol), sodium carbonate (43 mg, 0.40 mmol), water (65 ml) and DME (0.65 ml) was purged with nitrogen, sealed and heated to 80 °C for 14 h. Cooled to 20 °C , water was added (0.5 ml) and the mixture was purified by preparative RPHPLC. The product fractions were combined, treated with saturated sodium bicarbonate solution (20 ml) and extracted with ethyl acetate (2 X 50 ml). The organic extracts were combined, washed with brine (25 ml), dried (MgSO 4 ) and evaporated to leave a crystalline solid (28 mg, 54%). 1 
3-(8-Fluoronaphthalen-2-yl)-6-(4-methylpiperazin-1-yl)-4-(pyridin-4-yl)pyridazine (17 = MW032).
A mixture compound 2 (46 mg, 0.16 mmol), 2-(8-fluoronaphthalen-2-yl)-4,4,5,5tetramethyl-1,3,2-dioxaborolane (49 mg, 0.18 mmol), tetrakis(triphenylphosphine)palladium (18 mg, 16 mmol), sodium carbonate (43 mg, 0.40 mmol), water (65 ml) and DME (0.65 ml) was purged with nitrogen, sealed and heated to 80 °C for 14 h. Cooled to 20 °C , water was added (0.5 ml) and the mixture was purified by RPHPLC. The product fractions were combined, treated 
